Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mexico-US Genomics Partnership Launches Second Phase

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
SIGMA 2 is aimed at harnessing genomic medicine for the benefit of Latin America and the world.

SIGMA is an unprecedented partnership that aims to ensure that Latin Americans benefit from the genomic revolution by:

•    Promoting wider access to genomic medicine in Mexico and Latin America by supporting discovery programs that focus on health problems with particular relevance to the region, and leverage its unique population genetics, and
•    Enhancing genomic research capacity in Mexico through training of scientists and encouraging the development of genomic diagnostics and therapeutics in Latin America.

The partnership brings together three organizations — the Broad Institute, the Carlos Slim Health Institute, and the National Institute of Genomic Medicine of Mexico — with a shared commitment to transforming human health. The work will be carried out in coordination with scientists from Mexican institutions, like the National Autonomous University and the National Institute of Medical Sciences and Nutrition, led by the Carlos Slim Center for Health Research at the Broad Institute.

Carlos Slim Hélu, together with Broad Institute President and Director Eric Lander, announced SIGMA 2 during a special event on Monday at the Broad Institute.

“Most genomic research has focused on European or European-derived populations. It’s like doing science with one eye closed. There are many discoveries that can only be made by studying non-European populations,” said Dr. Lander. “In addition to the scientific importance of studies in Latin America, it is essential that the benefits of the genomic revolution be accessible to people throughout the Americas and the world.”

“I am incredibly grateful to Carlos Slim for his extraordinary commitment to improving public health,” added Dr. Lander.

SIGMA 2 aims to develop new biomedical approaches to some of the most crucial problems in public health, including cancer, type 2 diabetes, and kidney disease. It builds upon an initial effort launched in 2010 with the Carlos Slim Health Institute.

“The Broad Institute is a world leader in genomic medicine and shares our own vision for overcoming some of the greatest challenges and solutions in public health,” said Carlos Slim Hélu. “I am convinced that the discoveries we make together will strongly impact the population in Mexico and worldwide.”

With an initial donation of $65M by the Carlos Slim Foundation, in the first phase of SIGMA Broad scientists worked closely with Mexican colleagues and with researchers from across the Broad’s partner institutions to systematically identify genes underlying cancer, diabetes and kidney disease. The project yielded deep biomedical insights in each of its three core areas. These include:

•    In type 2 diabetes, scientists identified a common genetic variant predisposing Latin American populations to the disease. Because this genetic variant is absent in Europeans, it had been previously overlooked.
•    In cancer, researchers identified new genetic drivers of breast cancer, lymphoma, head and neck cancer, and other cancers.
•    In kidney disease, the Mexico-US team discovered the gene for medullary cystic kidney disease type 1 (MCKD1) — a rare disorder that ultimately requires dialysis or kidney transplantation.

The SIGMA 2 project, while continuing its early discovery efforts, will focus on translating these discoveries into clinical impact, including the development of diagnostic tools for breast cancer and diabetes, completing the genetic analysis of these diseases, creating therapeutic “roadmaps” to guide the development of new treatments, and the launching of a full-scale effort to target MCKD1.

In addition, SIGMA 2 will continue to work on building scientific capacity in the US and Mexico. In the initial phase, the project engaged scientists across 125 institutions in both countries. Going forward, the project will aim to substantially increase its collaborative scope.

“In just a few years, our work together with our colleagues in Mexico has been enormously productive and enriching to the scientific community,” said Dr. Lander. “It’s now time to expand this international partnership so that it truly benefits our children — both in Mexico and in the United States.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Better Living through Proteomics
As a patient facing illness, knowing what’s ailing you can bring peace of mind and, more importantly, can inform treatment decisions.
Monday, September 09, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!